Compare Infosys Limited (INFY) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Infosys Limited trades at $10.74 (market cap $41.69B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Infosys Limited is far larger — about 18.3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Infosys Limited pays a 4.96% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| INFY | SLS | |
|---|---|---|
Market Cap | $41.69B | $2.28B |
Volume | 28,397,442 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $20.22 | $15.46 |
52-Week Low | $10.49 | $1.39 |
Typical Hold Time | 27 Days | — |
Enterprise Value | $39.44B | $2.15B |
Dividend Yield | 4.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.55, showing no change recently. The stock is in a bearish technical trend, with moving averages signaling sell pressure, while oscillators are neutral. Fundamentally, the company reported $19.28B in revenue for 2025 with a net income margin of 16.37%, and valuation ratios like a P/E of 13.02 suggest relative affordability. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation. Earnings history is mixed, with a beat in Q1 2026 but a miss in Q2 2026.
The outlook for INFY is cautious, with analyst consensus at a $11.48 price target and a 'Hold' bias (55% of ratings). Opportunities include strong profitability metrics like a 32.12% ROE and AI-driven growth initiatives, but risks involve bearish technical signals, potential earnings volatility, and competitive pressures in IT services. Net cash flow turned negative in 2026, indicating financial strain, which could limit upside near-term.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
